TRDA ENTRADA THERAPEUTICS INC

Entrada Therapeutics to Present at Upcoming Investor Conferences

Entrada Therapeutics to Present at Upcoming Investor Conferences

BOSTON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today announced it will participate in the following two investor conferences:

Oppenheimer 34th Annual Healthcare Life Sciences Conference

Dipal Doshi, Chief Executive Officer, will participate in a virtual fireside chat on Wednesday, February 14, 2024, at 2:00 p.m. Eastern Time.

TD Cowen 44th Annual Health Care Conference

Nathan Dowden, President and Chief Operating Officer, will participate on the Orphan Bone & Neuromuscular Diseases panel on Monday, March 4, 2024, at 9:10 a.m. Eastern Time in Boston, MA.

Live webcasts will be available on the Investor Relations section of the Company’s website at . Replays will be available on the Entrada website for 90 days following the events.

About Entrada Therapeutics

Entrada Therapeutics is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines, Endosomal Escape Vehicle (EEV™)-therapeutics, to engage intracellular targets that have long been considered inaccessible and undruggable. The Company’s EEV therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Through its proprietary, highly versatile and modular EEV platform, Entrada is building a robust development portfolio of RNA-, antibody- and enzyme-based programs for the potential treatment of neuromuscular, immunological, ocular and metabolic diseases, among others. The Company’s lead oligonucleotide programs include ENTR-601-44, ENTR-601-45 and ENTR-601-50 for the potential treatment of people living with Duchenne who are exon 44, 45 and 50 skipping amenable, respectively, as well as our partnered candidate VX-670 for myotonic dystrophy type 1.

For more information about Entrada, please visit our website, , and follow us on .

Investor and Media Contact

Karla MacDonald

Chief Corporate Affairs Officer



EN
07/02/2024

Underlying

TRDAENTRADA THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ENTRADA THERAPEUTICS INC

 PRESS RELEASE
Free
TRDA ENTRADA THERAPE...

Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthc...

Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that Dipal Doshi, Chief Executive Officer, will deliver a company presentation at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 3:45 PM PT (6:45 PM ET). A live webcast will be available on the Presentations portion of Entrada’s Investor Relations website at . The webcast will be archived and available for replay for 30 days after the event. About Entrada Therapeutics...

December 17, 2025 1 EN
 PRESS RELEASE
Free
TRDA ENTRADA THERAPE...

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing ...

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that the Company granted an aggregate of 40,650 restricted stock units (“RSUs”) and options to purchase 38,850 shares of the Company’s common stock to five newly-hired non-executive employees under the Company’s 2025 Inducement Equity Plan (the “Inducement Plan”), effective as of December 1, 2025. The options have an exercise price of $9.91 per share, which is equal to the closing price of the Company's co...

December 4, 2025 1 EN
Jonathan Moreland
  • Jonathan Moreland
Free Trial
VAC Marriott Vacati...
WWW Wolverine World... ... (+48)

InsiderInsights Weekly Report: November 15, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

VAC MARRIOTT VACATIONS WORLDWIDE CORPORATION
WWW WOLVERINE WORLD WIDE INC.
RGP RESOURCES CONNECTION INC.
NCLH NORWEGIAN CRUISE LINE HOLDINGS LTD.
MTDR MATADOR RESOURCES COMPANY
FTAI FORTRESS TRANSPORTATION AND INFRASTRUCTURE INVESTORS LLC
FLDM FLUIDIGM
FDS FACTSET RESEARCH SYSTEMS INC.
AROW ARROW FINANCIAL CORP.
GAM GENERAL AMERICAN INVESTORS CO. INC.
WHF WHITEFIELD
FMC FMC CORPORATION
LPX LOUISIANA-PACIFIC CORPORATION
SXC SUNCOKE ENERGY INC.
ITGR INTEGER HOLDINGS CORPORATION
ICHR ICHOR HOLDINGS LTD.
KREF KKR REAL ESTATE FINANCE TRUST
NWPP NEW PEOPLES BANKSHARES INC.
REZI RESIDEO TECHNOLOGIES
WU INC.
AEYE THE WESTERN UNION COMPANY
AMCR AUDIOEYE INC
BW AMCOR PLC
THRY BABCOCK & WILCOX ENTERPRISES
UTZ THRYV HOLDINGS
OPEN UTZ BRANDS INC (A)
ACVA OPENDOOR TECHNOLOGIES INC.
UPST ACV AUCTIONS INC.
FRSH UPSTART HOLDINGS
CLVT FRESHWORKS INC.
TRDA CLARIVATE PLC
SG ENTRADA THERAPEUTICS INC
TBBK SWEETGREEN INC
BLND THE BANCORP
CRVO INC.
NEXT ETRACS DJ-UBS COMMODITY INDEX 2-4-6 BLEND
SPRU CERVOMED INC
LAW NEXTSOURCE MATERIALS INC.
MRAI SPRUCE POWER HOLDING CORP
BNTC CS DISCO INC
GF MARPAI
HYMC INC.
SENS BENITEC BIOPHARMA INC
BATRK THE NEW GERMANY FUND
INC.
HYCROFT MINING HOLDING CORPORATION
SENSEONICS HOLDINGS INC.
LIBERTY MEDIA CORP
11/16/25 November 16, 2025 1 EN
Jonathan Moreland
  • Jonathan Moreland
Free Trial
CRTO CRITEO S.A
BLMN Bloomin' Brands... ... (+35)

InsiderInsights.com Daily Ratings Report: November 12, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

CRTO CRITEO S.A
BLMN BLOOMIN' BRANDS INC.
NCLH NORWEGIAN CRUISE LINE HOLDINGS LTD.
DLY LYONDELLBASELL INDUSTRIES NV
KMPR KEMPER CORPORATION
GOOD GLADSTONE COMMERCIAL CORPORATION
FLDM FLUIDIGM
CROX CROCS INC.
ASA ASA
AROW ARROW FINANCIAL CORP.
LPX LOUISIANA-PACIFIC CORPORATION
SXC SUNCOKE ENERGY INC.
TAP MOLSON COORS BEVERAGE COMPANY CLASS B
REZI RESIDEO TECHNOLOGIES
FSK INC.
WU FS KKR CAPITAL CORP
AEYE THE WESTERN UNION COMPANY
AMCR AUDIOEYE INC
AIMD.P AMCOR PLC
DKNG AIM4 VENTURES
OPEN DRAFTKINGS INC
ACVA OPENDOOR TECHNOLOGIES INC.
FRSH ACV AUCTIONS INC.
TRDA FRESHWORKS INC.
SG ENTRADA THERAPEUTICS INC
FRST SWEETGREEN INC
BLND PRIMIS FINANCIAL CORP
GTE ETRACS DJ-UBS COMMODITY INDEX 2-4-6 BLEND
LAW GRAN TIERRA ENERGY INC.
MRAI CS DISCO INC
GF MARPAI
RMI INC.
THE NEW GERMANY FUND
INC.
RIVERNORTH OPPOR MUN INC FD INC
11/13/25 November 13, 2025 1 EN
 PRESS RELEASE
Free
TRDA ENTRADA THERAPE...

Entrada Therapeutics Reports Third Quarter 2025 Financial Results

Entrada Therapeutics Reports Third Quarter 2025 Financial Results -- Company on track to report ELEVATE-44-201 data from first patient cohort in Q2 2026 -- -- First patient dosed in ELEVATE-45-201 and the Company is on track to report data from the first patient cohort in mid-2026 -- -- Filed for regulatory authorization in U.K. to initiate ELEVATE-50-201, a global Phase 1/2 MAD clinical study of ENTR-601-50 -- -- Expected cash runway extended into Q3 2027 with $327 million in cash, cash equivalents and marketable securities as of September 30, 2025 -- BOSTON, Nov. 06, 2025 (GLOBE NEW...

November 6, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch